Ten post jest także dostępny w języku: polski
After the investments in Germany and Ukraine, the Polish network of clinical trials centres is also starting to operate in Spain. As a result, the Neuca Group, through its subsidiary Clinscience, acquired 100% of the shares in Experior. It is a company operating on the clinical trials market.
Experior: access to more than 50 clinical hospitals
Experior is a Clinical Research Organization (CRO) company, which has been developing in the Spanish market for almost 20 years, covering Spain, Italy, France, UK and Benelux. The main therapeutic areas include: oncology, neurology, infectious diseases and autoimmune diseases. The Spanish company also has expertise in the development of research projects in ATMP – advanced medical technologies. Also important from Neuca‘s point of view is the involvement of Experior in the development of services in the area of clinical trials planning, biostatistics and technology.
The founder of Experior – Jaime A. Ballester – will remain at Experior as Managing Director and Head of the Spanish market.
Development of clinical trials in the Neuca Group
The investment in Experior is part of the implementation of the clinical trials development strategy adopted in 2019 in the Neuca Group. It is the group’s fifth investment in this area this year and the third outside Poland. We have written about the previous ones in more detail here. It is worth noting that Pratia’s network of clinical centres has started cooperation with more than 50 hospitals in Spain in recent months to conduct joint clinical trials. According to Tomasz Dabrowski, responsible for the clinical trials business, Neuca currently employs nearly 60 coordinators in Spain supporting 250 research projects.
Neuca Group, owner of Pratia, operates in several areas of the healthcare market. It conducts wholesale of pharmaceuticals, produces medicines and dietary supplements under own brands (Synoptis Pharma), and manages a network of several dozen clinics under the Swiat Zdrowia brand.